Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + EPOCH in PTCL
NCT03586999Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in peripheral T-cell lymphoma (PTCL), sponsored by University of Colorado Denver. Primary endpoint: Complete Response Rate. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03586999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586999.